Bibault J E, Prevost B, Dansin E, Mirabel X, Lacornerie T, Dubus F, Lartigau E
Département universitaire de radiothérapie, université Lille II, CyberKnife Nord-Ouest, centre Oscar-Lambret, 3, rue Frédéric-Combemale, BP 307, 59020 Lille cedex, France.
Cancer Radiother. 2010 Dec;14(8):690-7. doi: 10.1016/j.canrad.2010.03.010. Epub 2010 Jul 31.
Stereotactic radiation therapy using the CyberKnife(®) has been introduced in France in 2006. Two treatment modalities are currently available: the first one (Synchrony(®)) is a real-time fiducial-based target tracking system, while the other (Xsight Lung Tracking [XLT] System(®)) is completely fiducial-free.
Sixty-eight patients were treated for a pulmonary tumor between June 2007 and November 2009. Since august 2008, the XLT System(®) was used for 26 patients. We report the necessary conditions for the XLT System (position, laterality and size of the tumor), the toxicity and outcome of this treatment.
Twenty-two patients were analyzed. Median follow-up was 6 months (min=3; max=16). Local control rate was 100%. The main toxicity was grade grade 1 pulmonary alveolitis (27%). No grade 3 or 4 toxicities were reported.
The high local control rate and low toxicity obtained with the CyberKnife(®) XLT System(®) suggest that such treatment is an alternative for inoperable patients.
射波刀立体定向放射治疗于2006年引入法国。目前有两种治疗方式：第一种（同步技术）是基于实时基准的目标跟踪系统，而另一种（Xsight肺部追踪系统）则完全无需基准。
2007年6月至2009年11月期间，68例肺部肿瘤患者接受了治疗。自2008年8月起，26例患者使用了Xsight肺部追踪系统。我们报告了使用该系统的必要条件（肿瘤的位置、侧别和大小）、这种治疗的毒性和结果。
对22例患者进行了分析。中位随访时间为6个月（最小值 = 3；最大值 = 16）。局部控制率为100%。主要毒性为1级肺泡炎（27%）。未报告3级或4级毒性反应。
射波刀Xsight肺部追踪系统获得的高局部控制率和低毒性表明，这种治疗是无法手术患者的一种选择。
Zotero 插件